chloroquine has been researched along with cp-55,940 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Carvalho, P; Cutler, SJ; Dale, OR; Elokely, KM; ElSohly, MA; Galal Osman, A; Gul, W; Husni, AS; Khan, S; Klein, ML; Radwan, M; Ross, SA; Slade, D; Yadav, VK | 1 |
2 other study(ies) available for chloroquine and cp-55,940
| Article | Year |
|---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Bioactive products from singlet oxygen photooxygenation of cannabinoids.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antiprotozoal Agents; Bacteria; Cannabinoids; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Fungi; Humans; Leishmania major; Microbial Sensitivity Tests; Parasitic Sensitivity Tests; Photochemical Processes; Plasmodium falciparum; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Singlet Oxygen | 2018 |